Drug intelligence / Profile preview

JRD-038

Development stage: Preclinical
Lead developer: Jingrui Pharmaceutical
Modality: Small Molecules

Overview

JRD-038 is a small molecule drug developed by Jingrui Pharmaceutical (Suzhou Co. Ltd.) that acts as a modulator of the ERN1 gene, targeting the protein IRE1 (Serine/threonine-protein kinase/endoribonuclease IRE1). Its mechanism involves modulation of IRE1 activity, which plays a role in the unfolded protein response and cellular stress signaling pathways. The drug is being investigated for its potential use in treating neoplasms such as metastatic breast cancer and multiple myeloma, as well as immune system and cardiovascular diseases. As of early 2025, JRD-038 remains in preclinical development[1][2].

Targets

ERN1 (Inositol-requiring enzyme 1 alpha)

Beyond the preview

Go deeper on JRD-038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRD-038.

Explore the full profile